ArticleJournal of hematology & oncology2024

The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study.

Dan-Yun Ruan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.